Liraglutide, a human GLP-1 analogue, lowers HbA(1c) independent of weight loss
Príomhchruthaitheoirí: | Schmidt, W, Gough, S, Madsbad, S, Zinman, B, Falahati, A, Toft, A, Sesti, G |
---|---|
Formáid: | Conference item |
Foilsithe / Cruthaithe: |
2009
|
Míreanna comhchosúla
Míreanna comhchosúla
-
Liraglutide Is Associated with Reduced Rates of Hypoglycemic Events Versus Glimepiride When Achieving Target HbA(1c)
de réir: Gough, S, et al.
Foilsithe / Cruthaithe: (2010) -
Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme.
de réir: Zinman, B, et al.
Foilsithe / Cruthaithe: (2012) -
Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: A meta-analysis of the liraglutide clinical trial programme
de réir: Zinman, B, et al.
Foilsithe / Cruthaithe: (2012) -
Liraglutide, a human GLP-1 analogue, significantly improves beta cell function in subjects with type 2 diabetes
de réir: Matthews, DR, et al.
Foilsithe / Cruthaithe: (2008) -
The imaging of insulinomas using a radionuclide-labelled molecule of the GLP-1 analogue liraglutide: a new application of liraglutide.
de réir: Jing Lv, et al.
Foilsithe / Cruthaithe: (2014-01-01)